Lophius Biosciences’ mission is to transform treatment paradigms and patient management with novel molecular diagnostic solutions for life threatening and highly-contagious infectious diseases. The core program addresses an unmet clinical need in tuberculosis (TB), a global epidemic affecting hundreds of millions of people. Lophius has developed a proprietary blood-based multi-marker solution, run on widely available platforms, to deliver a significant improvement on TB infection detection over existing approaches. Lophius is advancing biomarker combinations which would disrupt the field by being able to differentiate between active TB disease and latent TB infection. In addition, the company is commercializing a clinically validated CE marked diagnostic kit to individualize transplant patient management by personalized CMV disease risk stratification.